NasdaqGM - Delayed Quote
USD
CRISPR Therapeutics AG (CRSP)
51.63
-0.71
(-1.36%)
At close: May 1 at 4:00:01 PM EDT
51.42
-0.21
(-0.41%)
After hours: May 1 at 7:59:12 PM EDT
Trade CRSP on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for CRSP
- Previous Close
52.34 - Open
51.59 - Bid 37.08 x 100
- Ask 65.95 x 100
- Day's Range
50.60 - 52.55 - 52 Week Range
33.03 - 78.48 - Volume
1,034,560 - Avg. Volume
1,902,085 - Market Cap (intraday)
4.979B - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
-- - EPS (TTM)
-6.47 - Earnings Date (est.) May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
83.35
Recent News: CRSP
View More
Performance Overview: CRSP
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CRSP
1.54%
S&P 500 (^GSPC)
5.62%
1-Year Return
CRSP
36.84%
S&P 500 (^GSPC)
29.01%
3-Year Return
CRSP
5.20%
S&P 500 (^GSPC)
73.47%
5-Year Return
CRSP
60.67%
S&P 500 (^GSPC)
72.92%
Earnings Trends: CRSP
View MoreAnalyst Insights: CRSP
View MoreStatistics: CRSP
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
4.98B
-
Enterprise Value
3.21B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
122.27
-
Price/Book (mrq)
2.59
-
Enterprise Value/Revenue
84.52
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-15.76%
-
Return on Equity (ttm)
-30.18%
-
Revenue (ttm)
3.51M
-
Net Income Avi to Common (ttm)
-581.6M
-
Diluted EPS (ttm)
-6.47
Balance Sheet and Cash Flow
-
Total Cash (mrq)
1.98B
-
Total Debt/Equity (mrq)
10.76%
-
Levered Free Cash Flow (ttm)
-205.62M
Compare To: CRSP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: CRSP
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: CRSP
View More-
Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice Target -
Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice Target -
Crispr Earnings: Casgevy Sees Stronger Uptake as Early-Stage Pipeline Assets Make Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice Target -
Crispr Earnings: Casgevy Sees Stronger Uptake as Early-Stage Pipeline Assets Make Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice Target
